About Sodium/potassium-transporting ATPase subunit beta-2
Sodium/potassium-transporting ATPase subunit beta-2 (ATP1B2) is a protein
from Homo sapiens identified by UniProt accession
P14415, 290 residues long.
MolForge cross-references it against 0 known binders and
187 disease associations.
Target properties
| Protein name | Sodium/potassium-transporting ATPase subunit beta-2 |
|---|
| UniProt accession | P14415 |
|---|
| Gene | ATP1B2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 290 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (187)
Diseases linked to this target (Open Targets).
- platelet count · score 0.29
- sex hormone-binding globulin measurement · score 0.27
- neurodegenerative disease · score 0.25
- testosterone measurement · score 0.25
- body height · score 0.23
- snoring measurement · score 0.22
- pancreatic adenocarcinoma · score 0.22
- mean corpuscular hemoglobin concentration · score 0.21
- esophageal squamous cell carcinoma · score 0.20
- Red cell distribution width · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P14415-F1 | alphafold | PREDICTED | 89.90 | — |
Amino-acid sequence (290 residues)
MVIQKEKKSC GQVVEEWKEF VWNPRTHQFM GRTGTSWAFI LLFYLVFYGF LTAMFTLTMW VMLQTVSDHT PKYQDRLATP GLMIRPKTEN LDVIVNVSDT ESWDQHVQKL NKFLEPYNDS IQAQKNDVCR PGRYYEQPDN GVLNYPKRAC QFNRTQLGNC SGIGDSTHYG YSTGQPCVFI KMNRVINFYA GANQSMNVTC AGKRDEDAEN LGNFVMFPAN GNIDLMYFPY YGKKFHVNYT QPLVAVKFLN VTPNVEVNVE CRINAANIAT DDERDKFAGR VAFKLRINKT
Explore Sodium/potassium-transporting ATPase subunit beta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets